May 22, 2026

DNS Africa Resource Center

..sharing knowledge.

As new cell and gene therapies emerge from academia, we must RISE to the opportunity – Nature.com


Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Advertisement
Career feature
Nature Biotechnology volume 43pages 143–146 (2025)
Metrics details
Academic medical centers must play a crucial part in overcoming cell and gene therapy development hurdles by establishing institutional frameworks that offer comprehensive support extending beyond financial assistance.
This is a preview of subscription content, access via your institution

Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
£14.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
£139.00 per year
only £11.58 per issue
Buy this article
Prices may be subject to local taxes which are calculated during checkout
Saez-Ibañez, A. R. et al. Nat. Rev. Drug Discov. 21, 631–632 (2022).
Article  PubMed  Google Scholar 
Kuzmin, D. A. et al. Nat. Rev. Drug Discov. 20, 173–174 (2021).
Article  CAS  PubMed  Google Scholar 
Vokinger, K. N., Avorn, J. & Kesselheim, A. S. N. Engl. J. Med. 388, 292–295 (2023).
Article  PubMed  Google Scholar 
Seyhan, A. A. Transl. Med. Commun. 4, 1–19 (2019).
Article  Google Scholar 
NEWDIGS Consortium at Tufts Medical Center. Are cell and gene therapy programs a better bet? Tufts Medical Center https://newdigs.tuftsmedicalcenter.org/wp-content/uploads/2023/10/NEWDIGS-Success-Rate-Comparison-2023F210v056.pdf (Tufts Medicine, 9 October 2023).
Cohen, J. P. Science continues to outpace commericalization of cell and gene therapies. Forbes Newslett. https://www.forbes.com/sites/joshuacohen/2024/03/04/science-continues-to-outpace-commercialization-of-cell-and-gene-therapies/ (2024).
RePORT. Estimates of funding for various research, condition, and disease categories (RCDC). NIH https://report.nih.gov/funding/categorical-spending#/ (14 May 2024).
Kassir, Z., Sarpatwari, A., Kocak, B., Kuza, C. C. & Gellad, W. F. J. Am. Med. Assoc. 323, 890–891 (2020).
Article  Google Scholar 
Aiuti, A., Pasinelli, F. & Naldini, L. Nat. Med. 28, 1985–1988 (2022).
Article  CAS  PubMed  Google Scholar 
Fox, T. et al. Nat. Med. 29, 518–519 (2023).
Article  CAS  PubMed  Google Scholar 
Lee, N. K. & Chang, J. W. Ann. Lab. Med. 44, 314–323 (2024).
Article  CAS  PubMed  PubMed Central  Google Scholar 
Scher, J. U. & Schett, G. Nat. Rev. Rheumatol. 17, 119–124 (2021).
Article  PubMed  Google Scholar 
Download references
Gene and Cell Therapy Institute, Mass General Brigham, Cambridge, MA, USA
Nandhitha Uma Naresh, Dana Hammill, Roger J. Hajjar & Nathan L. Yozwiak
New York, NY, USA
Mark Kessel
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
Correspondence to Nathan L. Yozwiak.
Reprints and permissions
Uma Naresh, N., Hammill, D., Kessel, M. et al. As new cell and gene therapies emerge from academia, we must RISE to the opportunity. Nat Biotechnol 43, 143–146 (2025). https://doi.org/10.1038/s41587-024-02520-9
Download citation
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-024-02520-9
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Advertisement
Nature Biotechnology (Nat Biotechnol) ISSN 1546-1696 (online) ISSN 1087-0156 (print)
© 2025 Springer Nature Limited
Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

source

About The Author